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Two years ago, at the ECRD in Krakow, we were celebrat-
ing the recommendation of the Council of Ministers on an
action in the field of rare diseases: this recommendation
requests that Member States define and implement a plan
or a strategy for rare diseases by the end of 2013 and asks
the European Commission to establish a EU Committee of
Experts in the field of Rare Diseases (EUCERD) as a forum
of stakeholders to propose action points at EU level. Two
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Figure 1 Emergence of concepts and initiatives surrounding rare diseases in Europe.
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years on, there is enough evidence to judge the outcome of
Recommendation which can be qualified as positive
despite the economic crisis. The dynamic of action is still
impressive (Figure 1). The EUCERD has been established
and fulfills its mission as expected. The publication of the
EUCERD annual report on the state of art of rare disease
activities in Europe testifies the many achievements [1].
The EUCERD adopted a set of quality criteria for the des-
ignation of centres of expertise for rare diseases at national
level. This work served as a basis for the working group on
centres of expertise in the framework of the Cross Border
Healthcare Directive. All countries are now engaged in the
process of elaborating a plan or a strategy for rare diseases
(Figure 2). The recent developments in genomics now
translate into more diagnostic tests for rare diseases. So
far over 1,800 rare diseases can be tested in one EU coun-
try. Targeted funding for rare diseases has also produced
its effects, with more transnational cooperation which
translated into the important decision to establish an
International Consortium to fund research: the IRDiRC.
The Consortium will allow more ambitious goals to be set
and achieved faster and it will ease the mobilisation of the
critical mass of expertise and resources whilst avoiding
overlaps in research. The Regulation on Orphan Medicinal
Products is still producing positive effects with currently
over 70 products with a marketing authorisation in the EU
Figure 2 Current stages of development of national plans or strategies for rare diseases in EU MS (in December 2011).
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and many more in development. The Orphanet database
became a Joint Action between all Member States, show-
ing the great degree of willingness to provide unified,
high-quality information to all EU citizens. Last but not
least, patient organisations are increasingly better orga-
nised to make their voice heard. Not only is EURORDIS
the voice of patients in Europe, but umbrella organisations
have been established in most countries (Figure 3).
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Figure 3 Countries in Europe with a national alliance for rare disease patient organisations and year founded
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